2022 Fiscal Year Final Research Report
Development of nuclear medicine imaging method targeting alfa-synuclein aggregates for diagnosis and treatment of Lewy body disease.
Project/Area Number |
20H03622
|
Research Category |
Grant-in-Aid for Scientific Research (B)
|
Allocation Type | Single-year Grants |
Section | 一般 |
Review Section |
Basic Section 52040:Radiological sciences-related
|
Research Institution | Kyoto University |
Principal Investigator |
Ono Masahiro 京都大学, 薬学研究科, 教授 (80336180)
|
Co-Investigator(Kenkyū-buntansha) |
渡邊 裕之 京都大学, 薬学研究科, 講師 (40710786)
志水 陽一 京都大学, 医学研究科, 講師 (90634212)
飯國 慎平 京都大学, 薬学研究科, 助教 (70837731)
|
Project Period (FY) |
2020-04-01 – 2023-03-31
|
Keywords | αシヌクレイン |
Outline of Final Research Achievements |
In this study, I investigated structure-activity kinetic relationships using a compound library to develop novel radioligand molecular imaging probes for PET/SPECT that enable biomolecular imaging of α-synuclein aggregates expressed in the brain in Lewy body disease. As a result, I found chalcone analogues that exhibit excellent binding affinity and selectivity for α-synuclein aggregates. This probe was successfully performed to detect α-synuclein aggregates in vivo, indicating its usefulness as an α-synuclein imaging probe for PET.
|
Free Research Field |
放射性薬品化学
|
Academic Significance and Societal Importance of the Research Achievements |
本研究で開発した新規プローブを用いたαシヌクレインの生体イメージングが可能となれば,レビー小体病の早期診断への応用が期待できる .さらに,現在αシヌクレインを標的とした凝集阻害剤の開発研究も活発に行われており,その生体イメージングは,治療薬のスクリーニングツールとしても応用可能であることから,αシヌクレインを標的分子とするレビー小体病の創薬研究への貢献も期待できる.
|